Eli Lilly and Co

• Novo Nordisk's 'long game' on weight loss drugs sparks hope in science, but the Street is impatient - The medicine developed by the100-year old Danish drugmaker may impact patients' brains in surprising ways
• We're buying the post-earnings slump in a stock alongside Tim Cook. It's not Apple - We're scooping up shares of struggling company on a confidence-inducing signal from the board of directors that a bottom could be forming.
• Shares in Wegovy-maker Novo Nordisk pop 6% after GLP-1 pill approval - The FDA on Monday approved the first-ever GLP-1 pill from the Danish pharmaceutical giant.
• Nine of the largest pharma companies ink deals with Trump to lower drug prices - President Donald Trump has pushed to lower drug prices for Americans, which are on average nearly three times higher than overseas.
• Eli Lilly's next-generation obesity drug delivers strong weight loss, reduces knee pain in late-stage trial   - The drugmaker is betting big on retatrutide as the next pillar of its obesity portfolio after its weight loss injection Zepbound and its upcoming pill. 
• Eli Lilly cuts cash prices of Zepbound weight loss drug vials on direct-to-consumer site - The announcement comes weeks after President Donald Trump inked deals with Eli Lilly and Novo Nordisk to make their GLP-1 drugs easier for Americans to access.